STOCK TITAN
  1. Home
  2. News
  3. OSMT

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets.

Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:

DateMonday, November 15, 2021
Time4:30 p.m. ET
Toll free (U.S.)(866) 672-5029
International(409) 217-8312
Conference ID57399556
Webcast (live and replay)www.osmotica.com under the “Investor & News” section

About Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ®.

Osmotica has operations in the United States and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com


Stock OSMT logo
OSMT

NASDAQ:OSMT

OSMT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

OSMT Latest News

Jan 19, 2022
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
Jan 19, 2022
Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
Jan 18, 2022
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
Jan 6, 2022
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
Dec 20, 2021
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

OSMT Stock Data

0
32.31M
0.28%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Bridgewater

About OSMT

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.